Suppr超能文献

[对转染醛糖还原酶样基因-1(ARL-1)的HepG2细胞系中耐药相关基因的筛选]

[Screening of the drug resistance-associated gene in HepG2 cell line transfected with aldose reductase like gene-1 (ARL-1)].

作者信息

Yang Xiang-Dong, Tang Da-Nian, Wang Jian, Cao De-Liang

机构信息

Centre of Molecular Biology, Nanhua University, Hengyang, Hunan, PR China.

出版信息

Ai Zheng. 2003 Dec;22(12):1289-95.

Abstract

BACKGROUND & OBJECTIVE: Aldose reductase like gene-1 overexpresses in hepatocellular carcinomas; it might be the drug resistance- associated gene to anti-tumor drugs containing carbonyl groups on hepatocellular carcinomas. This study was designed to establish human hepatocellular carcinoma cell line (HepG2) transfected with aldose reductase like gene-1 (ARL-1), then to observe the changes of drug resistance to anti-tumor drugs with carbonyl group and screen the drug resistance-associated genes through cDNA chip.

METHODS

PBK/ARL-1 plasmid was transfected to HepG2 cells by liposome to establish HepG2 monoclonal cells with high expression of ARL-1. The HepG2 cells with high expression of ARL-1 were determined by reverse transcription-polymerase chain reaction (RT-PCR),flow cytometric analysis (FCA), and immunohistochemical staining. MTT assay and cell apoptosis analysis were performed to determine the drug resistance ability of the cells to Adriamycin (ADM) and mytomycin (MMC), which contain carbonyl group. 5-fluorouracil (5-FU) that has no carbonyl group was used as control. Then two kinds of cDNA probes were made from HepG2 cells and ARL-HepG2 cells and labeled with Cy3 and Cy5 dyes. The probes were hybridized to the human liver cDNA chip and differentially expressed genes from the two cells were screened. The genes could be involved in drug resistance were confirmed by RT-PCR and Western blot.

RESULTS

Compared with HepG2 cells, HepG2 cells transfected with ARL-1 gene have an increase in expression of ARL-1. Drug resistance ability of HepG2 cells transfected with ARL-1 gene to ADM and MMC increased 2.6 and 3.47 folds, respectively (t=6.39, P< 0.05 in ADM group; t=30.06, P< 0.01 in MMC group). Drug resistance to 5-FU had no statistical difference between them (t=0.684,P >0.05 in 5-FU group). 15 genes down-regulated and 9 genes up-regulated after transfected with ARL-1 gene were found by cDNA chip scanned. Some differentially displayed genes such as ubiquitin and MDR confirmed by RT-PCR and Western blot were consistent to the results of cDNA chip.

CONCLUSION

The HepG2 cells with high expression of ARL-1 have more drug resistance to anti-tumor drugs with carbonyl group. Up-regulated MDR expression and down-regulated ubiquitin expression may contribute to the drug resistance of HepG2 cells.

摘要

背景与目的

醛糖还原酶样基因-1在肝细胞癌中过表达,可能是肝细胞癌对含羰基抗肿瘤药物的耐药相关基因。本研究旨在构建转染醛糖还原酶样基因-1(ARL-1)的人肝癌细胞系(HepG2),观察其对含羰基抗肿瘤药物耐药性的变化,并通过cDNA芯片筛选耐药相关基因。

方法

采用脂质体介导将PBK/ARL-1质粒转染至HepG2细胞,建立ARL-1高表达的HepG2单克隆细胞。通过逆转录-聚合酶链反应(RT-PCR)、流式细胞术分析(FCA)及免疫组化染色鉴定ARL-1高表达的HepG2细胞。采用MTT法及细胞凋亡分析检测细胞对含羰基的阿霉素(ADM)及丝裂霉素(MMC)的耐药能力,以不含羰基的5-氟尿嘧啶(5-FU)作为对照。分别提取HepG2细胞及ARL-HepG2细胞的总RNA,逆转录合成cDNA,制备两种cDNA探针,分别用Cy3和Cy5荧光染料标记。将探针与人类肝脏cDNA芯片杂交,筛选两种细胞差异表达的基因,对可能参与耐药的基因进行RT-PCR及Western blot验证。

结果

与HepG2细胞相比,转染ARL-1基因的HepG2细胞ARL-1表达增加。转染ARL-1基因的HepG2细胞对ADM和MMC的耐药能力分别增加2.6倍和3.47倍(ADM组t=6.39,P<0.05;MMC组t=30.06,P<0.01)。对5-FU的耐药性两者无统计学差异(5-FU组t=0.684,P>0.05)。cDNA芯片扫描发现转染ARL-1基因后15个基因下调,9个基因上调。RT-PCR及Western blot验证的泛素、多药耐药等部分差异表达基因与cDNA芯片结果一致。

结论

ARL-1高表达的HepG2细胞对含羰基抗肿瘤药物具有更强的耐药性。多药耐药基因表达上调及泛素表达下调可能与HepG2细胞的耐药有关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验